Focus: Molecular Devices is a biotechnology company specializing in lab equipment, machines, and servicing for research and drug development. Founded in 1983 and headquartered in San Jose, CA, it operates as a mid-scale provider serving multiple therapeutic areas.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Hot — 1933 jobs added in 30d
Net +1144 (1933 new, 789 removed). Aggressive expansion phase.
Stable infrastructure play with near-term hiring but uncertain long-term direction; suitable for operations/engineering roles, risky for those betting on pipeline growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generates 24% of company revenue but faces biosimilar and generic competition in mature market.
Help build intelligence for Molecular Devices
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Molecular Devices's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue contributor in a post-exclusivity market with limited growth potential.
Stable neurology asset serving a chronic disease indication with steady demand.
Oncology revenue stream in competitive aromatase inhibitor class with mature market.
Orphan/supportive care indication with niche market and limited upside.
Cardiovascular generic in saturated market with significant generic competition.
Metabolic disease therapy in competitive generic space with limited differentiation.
Diabetes therapy in commoditized generic market with declining utilization.
Infectious disease therapy for parasitic infections with stable niche demand.
Pain/muscle relaxant in mature market facing OTC and prescription alternatives.
527 discontinued, 235 duplicate formulations not shown
+3 more products with revenue data
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
+227 more products
Recent mass layoff at HQ contradicts aggressive hiring numbers; organization may be consolidating roles or exiting product lines.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo